US approves radiation-based prostate cancer drug

(AP)—The U.S. Food and Drug Administration has approved a new injectable drug that uses radiation to treat advanced prostate cancer that has spread to the bones.

The FDA said Wednesday it approved the drug, Xofigo from Bayer Pharmaceuticals, for men whose cancer has grown into bone tumors even after receiving medication or surgery to lower testosterone. The hormone spurs growth of .

Regulators approved Xofigo based on a study of 809 men with advanced prostate cancer who received the drug or placebo. Patients taking Xofigo typically lived 14 months compared to 11.2 months for those taking placebo.

Xofigo's side effects include nausea and diarrhea.


Explore further

FDA expands approval of Bayer cancer drug (Update)

© 2013 The Associated Press. All rights reserved.

Citation: US approves radiation-based prostate cancer drug (2013, May 15) retrieved 31 July 2021 from https://medicalxpress.com/news/2013-05-radiation-based-prostate-cancer-drug.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments